1. Tokarz, V.L.; MacDonald, P.E.; Klip, A. The cell biology of systemic insulin function. J. Cell Biol. 2018, 217, 2273–2289. [CrossRef] [PubMed]
2. Rieg, T.; Vallon, V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 2018, 61, 2079–2086. [CrossRef] [PubMed]
3. Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl.J. Med. 2019, 380, 2295–2306. [CrossRef] [PubMed]
4. DeFronzo, R.A.; Norton, L.; Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 2017, 13, 11–26. [CrossRef] [PubMed]
5. McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Beˇlohlávek, J.; et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019, 381, 1995–2008. [CrossRef] [PubMed]
6. Flores, E.; Santos-Gallego, C.G.; Diaz-Mejia, N.; Badimon, J.J. Do the SGLT-2 inhibitors offer more than hypoglycemia activity? Cardiovasc. Drugs Ther. 2018, 32, 213–222. [CrossRef]
7. Barron, C.C.; Bilan, P.J.; Tsakiridis, T.; Tsiani, E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism 2016, 65, 124–139. [CrossRef] [PubMed]
8. Liu, Y.; Zhang, Z.; Wang, J.; Chen, C.; Tang, X.; Zhu, J.; Liu, J. Metabolic reprogramming results in abnormal glycolysis in gastric cancer: A review. Onco Targ. Ther. 2019, 12, 1195–1204. [CrossRef]
9. Saito, T.; Okada, S.; Yamada, E.; Shimoda, Y.; Osaki, A.; Tagaya, Y.; Shibusawa, R.; Okada, J.; Yamada, M. Effect of dapagliflozin on colon cancer cell. Endocr. J. 2015, 62, 1133–1137. [CrossRef] [PubMed]
10. Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos. 2010, 38, 405–414. [CrossRef] [PubMed]
11. Saito, T.; Okada, S.; Yamada, E.; Ohshima, K.; Shimizu, H.; Shimomura, K.; Sato, M.; Pessin, J.E.; Mori, M. Syntaxin 4 and Synip (syntaxin 4 interacting protein) regulate insulin secretion in the pancreatic beta HC-9 cell. J. Biol. Chem. 2003, 278, 36718–36725. [CrossRef] [PubMed]
12. Multhaupt, H.A.; Leitinger, B.; Gullberg, D.; Couchman, J.R. Extracellular matrix component signaling in cancer. Adv. Drug. Deliv. Rev. 2016, 97, 28–40. [CrossRef] [PubMed]
13. Kothiwale, S.; Borza, C.M.; Lowe, E.W., Jr.; Pozzi, A.; Meiler, J. Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery. Drug. Discov. Today. 2015, 20, 255–261. [CrossRef] [PubMed]
14. Shitomi, Y.; Thøgersen, I.B.; Ito, N.; Leitinger, B.; Enghild, J.J.; Itoh, Y. ADAM10 controls collagen signaling and €b0cell migration on collagen by shedding the ectodomain of discoidin domain receptor 1 (DDR1). Mol. Biol. Cell 2015, 26, 659–673. [CrossRef] [PubMed]
15. Leitinger, B. Discoidin domain receptor functions I physiological and pathological conditions. Int. Rev. Cell Mol. Biol. 2014, 310, 39–87. [PubMed]
16. Vogel, W.F. Ligand-induced shedding of discoidin domain receptor 1. FEBS. Lett. 2002, 514, 175–180. [CrossRef]
17. Shiba, K.; Tsuchiya, K.; Komiya, C.; Miyachi, Y.; Mori, K.; Shimazu, N.; Yamaguchi, S.; Ogasawara, N.; Katoh, M.; Itoh, M.; et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 2018, 8, 2362. [CrossRef] [PubMed]
18. Scafoglio, C.R.; Villegas, B.; Abdelhady, G.; Bailey, S.T.; Liu, J.; Shirali, A.S.; Wallace, W.D.; Magyar, C.E.; Grogan, T.R.; Elashoff, D.; et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci. Transl. Med. 2018, 10, 5933. [CrossRef] [PubMed]
19. Wang, L.; Liu, M.; Yin, F.; Wang, Y.; Li, X.; Wu, Y.; Ye, C.; Liu, J. Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells. Molecules 2019, 24, 3390. [CrossRef] [PubMed]
20. Okada, J.; Matsumoto, S.; Kaira, K.; Saito, T.; Yamada, E.; Yokoo, H.; Katoh, R.; Kusano, M.; Okada, S.; Yamada, M. Sodium glucose cotransporter 2 inhibition combined with cetuximab significantly reduced tumor size and carcinoembryonic antigen level in colon cancer metastatic to liver. Clin. Colorectal Cancer 2018, 17, e45–e48. [CrossRef] [PubMed]